Online inquiry

IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ437MR)

This product GTTS-WQ437MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets AMHR2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001164690.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 269
UniProt ID Q16671
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ437MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13138MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA PF-04360365
GTTS-WQ10027MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ11538MR IVTScrip™ mRNA-Anti-CD3E, MGA031(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MGA031
GTTS-WQ65MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ7107MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ14604MR IVTScrip™ mRNA-Anti-DLL3, SC0001(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SC0001
GTTS-WQ10878MR IVTScrip™ mRNA-Anti-B4GALNT1, MAb-14.18(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MAb-14.18
GTTS-WQ3257MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ART621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW